EMERYVILLE, CA, Ansa Biotechnologies announced that it has closed $45.2M and secured commitments for an additional $9.2M as part of a series B financing round.
Ansa Biotechnologies, a trusted partner for DNA synthesis, announced that it has closed $45.2 million and secured commitments for an additional $9.2 million as part of an oversubscribed series B financing round. The round was led by Cerberus Ventures with participation from Blue Water Life Science Advisors, Altitude Life Science Ventures, and other existing investors. New investors include Fall Line Capital, AIM13, and Black Opal Ventures.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
